ArticleBMC surgery2021
Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study.
Article in BMC surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Is there a chance for curative treatment for metastatic pancreatic adenocarcinoma? A systematic review with meta-analysis.Langenbeck's archives of surgery · 2025Pooled it
- The role of pulmonary metastasectomy in patients suffering pancreatic ductal adenocarcinoma with lung metastases: a systematic review and meta-analysis.Frontiers in surgery · 2025Pooled it
- Pulmonary Metastases After Surgical Resection of Pancreatic Ductal Adenocarcinoma: Impact on Long-Term Survival and Perspectives on Targeted Treatments.Annals of surgical oncology · 2026Article
- A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy.Clinical journal of gastroenterology · 2026Article
- Exceptional Long-Term Survival after Resection of Metachronous Liver and Lung Metastases Following Surgery for Pancreatic Cancer: A Case Report.Surgical case reports · 2026Article
- Risk and prognostic factors of survival for patients with pancreatic ductal adenocarcinoma metastasis to lung: a cohort study.Frontiers in oncology · 2025Article
- Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.Japanese journal of clinical oncology · 2024Review
- Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis.ESMO gastrointestinal oncology · 2023Article
- Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma.Annals of gastroenterological surgery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary metastases from pancreatic ductal adenocarcinoma (PDAC) are relatively rare. Systemic chemotherapy is the first choice of treatment in patients with distant metastases, and the role of metastasectomy is controversial. The aim of the present study was to evaluate the outcome of patients with pulmonary metastases after resection of PDAC and the indications for metastasectomy.
methodsWe retrospectively analysed patients with pulmonary metastases as the first recurrence after resection of primary PDAC between January 2006 and December 2018. Clinical data were obtained from the patients' medical records. Relapse-free survival (RFS) and overall survival (OS) were analysed using the Kaplan-Meier method, and statistical significance was evaluated by the log-rank test.
resultsOf the 417 patients with resected PDACs, 24 (7.9%) had pulmonary metastases. Six patients (25.0%) underwent pulmonary resection and 18 (75.0%) received systemic chemotherapy and best supportive care. There were no major complications requiring therapeutic intervention after pulmonary resection. The median RFS was 24.0 months (95% CI 10.8-37.2), and the 1-, 3-, and 5-year RFS rates were 66.7%, 33.3%, and 4.2%, respectively. The median OS was 50.0 months (95% CI 15.9-84.1), and the 1-, 3-, and 5-year OS rates were 95.8%, 70.3%, and 46.4%, respectively. All patients with resected pulmonary metastases were alive at the end of the study, whereas the median OS of the patients who did not undergo resection was 37.0 months (95% CI 34.4-39.6). Therefore, patients with resected pulmonary metastases had a significantly better prognosis (p = 0.008).
conclusionsPulmonary resection may improve the prognosis in selected patients with pulmonary metastases from PDAC. However, the present study is based on a small number of patients and may include a selection bias; therefore, a multi-institutional prospective study is needed to clarify the indications for pulmonary resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.